Federation des caisses Desjardins du Quebec’s VanEck Vectors Generic Drugs ETF GNRX Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio GNRX Stock Details GNRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-1,141	Closed	-$25.3K	–	2239
2017 Q3	$25.3K	Hold	1,141	–	–	﹤0.01%	1483
2017 Q2	$25.9K	Hold	1,141	–	–	﹤0.01%	1534
2017 Q1	$25.7K	Buy	+1,141	New	+$25.3K	﹤0.01%	1257

Other funds holding GNRX

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

APA

American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's GNRX Position: Q4 2017 in Review

Federation des caisses Desjardins du Quebec sold out of VanEck Vectors Generic Drugs ETF (GNRX) in Q4 2017, closing a stake of 1,141 shares — an estimated $25.3K sold.

Federation des caisses Desjardins du Quebec first reported a position in GNRX in Q1 2017 and held it in 3 quarters. The position peaked at $25.9K in Q2 2017. 4 funds tracked by Wall St. Rank hold GNRX as of Q4 2017.

Federation des caisses Desjardins du Quebec reported no remaining VanEck Vectors Generic Drugs ETF position as of Q4 2017 after selling out during the quarter.
Federation des caisses Desjardins du Quebec sold 1,141 VanEck Vectors Generic Drugs ETF shares in Q4 2017, an estimated $25.3K.
Federation des caisses Desjardins du Quebec first reported a position in VanEck Vectors Generic Drugs ETF in Q1 2017 and held it in 3 quarters.
Federation des caisses Desjardins du Quebec's VanEck Vectors Generic Drugs ETF position peaked at $25.9K in Q2 2017.
4 funds tracked by Wall St. Rank held VanEck Vectors Generic Drugs ETF as of Q4 2017.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q4 2017, filed 30 Aug 2024.